GCM
TYRA icon

Graham Capital Management’s Tyra Biosciences TYRA Stock Holding History

Graham Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,756
Closed -$220K – 1519
2026
Q1 		$220K Buy
+5,756
New +$186K 0.01% 926

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Graham Capital Management's TYRA Position: Q2 2026 in Review

Graham Capital Management sold out of Tyra Biosciences (TYRA) in Q2 2026, closing a stake of 5,756 shares — an estimated $220K sold.

Graham Capital Management first reported a position in TYRA in Q1 2026 and held it in 1 quarter. The position peaked at $220K in Q1 2026. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Graham Capital Management reported no remaining Tyra Biosciences position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 5,756 Tyra Biosciences shares in Q2 2026, an estimated $220K.
  • Graham Capital Management first reported a position in Tyra Biosciences in Q1 2026 and held it in 1 quarter.
  • Graham Capital Management's Tyra Biosciences position peaked at $220K in Q1 2026.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.